Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma

Area of Science:

• Oncology
• Pharmacogenomics
• Molecular Biology

Background:

• Metastatic renal cell carcinoma (mRCC) prognosis has improved with molecular-targeted therapies.
• These targeted drugs can cause diverse adverse reactions, impacting treatment efficacy.
• Predictive markers are crucial for managing adverse drug reactions (ADRs) and optimizing cancer therapy.

Purpose of the Study:

• To review genetic polymorphisms associated with molecular-targeted therapy-induced adverse reactions in mRCC patients.
• To integrate perspectives on genetic factors influencing specific adverse responses.
• To discuss the relationship between drug exposure and ADRs.

Main Methods:

• Literature review of genetic polymorphisms in mRCC patients undergoing targeted therapy.
• Analysis of pharmacokinetic and pharmacodynamic mechanisms of genetic influences on ADRs.
• Discussion of systemic drug exposure in relation to adverse events.

Main Results:

• Summary of genetic polymorphisms linked to targeted therapy ADRs in mRCC.
• Exploration of how genetic variations affect drug metabolism and action.
• Correlation between drug exposure levels and the occurrence of ADRs.

Conclusions:

• Genetic polymorphisms play a significant role in mRCC patients' response to targeted therapies.
• Understanding these genetic factors is key to predicting and mitigating ADRs.
• Personalized medicine approaches using pharmacogenomics can enhance treatment outcomes for mRCC.